
Dr. Pete Jackson
Board member BEAM Alliance, CEO Infex Therapeutics Ltd, Non-Exec Chair Norwich Research Park
Ten years on from the antimicrobial resistance (AMR) Review, the UK’s antimicrobial subscription model proves new antibiotics can be funded sustainably. Discover why a global standard is now essential.
Ten years ago, the UN General Assembly, the Davos Declaration and the UK’s AMR Review led by Jim O’Neill launched global political awareness of AMR: microbes evolving rapidly to resist life-saving antibiotics.
Since then, understanding has broadened beyond public health to the structural barriers to innovation, chief among them a market model that fails to incentivise antimicrobial innovation. We badly need a new pipeline of treatments for critical infections, but we must also use new drugs sparingly to prevent further resistance. That means companies cannot recoup development costs the conventional way, by increasing sales.
Paying differently for antimicrobials
For years, the proposed answer has been to value and pay for antimicrobials differently: providing sustainable revenue without incentivising ever-higher use. The idea that has attracted most policy attention is the UK’s antimicrobial subscription model.
Following an earlier pilot, it launched in 2024 as a permanent, £1.9 billion, 16-year scheme, paying up to £24 million a year per qualifying treatment to guarantee availability for NHS clinicians.1 On its own, it is not large enough to solve the problem globally, but it shows a workable mechanism exists and that the UK has played its part.
Evaluation criteria should follow a shared, agreed framework, giving developers clarity and minimising cross-border bureaucracy
International action on AMR
Momentum is building elsewhere, with pilots and draft legislation in development across the EU and its member states, the US, Canada, Japan and Switzerland. The UK can accelerate progress by sharing five years of operational experience, and experts from NICE and the NHS have signalled they are open to dialogue. The priority now is for other countries to engage actively, aiming for a global standard others can adopt with confidence.
This is not about any one country claiming primacy, but about consistency across schemes. Evaluation criteria should follow a shared, agreed framework, giving developers clarity and minimising cross-border bureaucracy. Local health needs matter, but the underlying principles should be standardised. Countries with a too-narrow domestic focus risk exposure to AMR threats emerging elsewhere and may miss out on vital new drugs for their patients.
International action on awareness catalysed the AMR response a decade ago: let’s implement an agreed global solution to develop a new armoury of treatments.
Global Cause